Με επιφυλαξη

[Perseus1966]

Νεκροταφειο στη Φιλαδελφεια ,δεν προλαβαινουν λεει να θαβουν τους σκοτωμενους.

ψεκομπολια στο Φιλα!

[Προέλλην]

Αν το έγραψε ο Κρίς ο Κόνελ στο Τουίτερ, πολύ καλά κάνεις και επιφυλάσσεσαι.

Τώρα. γιατί αποτελεί άξια λόγου είδηση το τι έγραψε ο κάθε καθυστερημένος στο ακάου του

[nemo]

ετσι θα γινει και η αθηνα σε λιγα χρονια με φιλελε και κομμουνισμο

[Προέλλην]

Δεν τραβάτε σε κανά γιατρό

[Perseus1966]

Αν το έγραψε ο Κρίς ο Κόνελ στο Τουίτερ, πολύ καλά κάνεις και επιφυλάσσεσαι.

Τώρα. γιατί αποτελεί άξια λόγου είδηση το τι έγραψε ο κάθε καθυστερημένος στο ακάου του

Ειδηση απιτελει οτι σκωτονινται σαν τα ζωα ,οχι τι γραφει ο καθε " καθυστερημενος"

[vallon]

νομίζεις ότι ενδιαφέρεται για το τι συμβαίνει στον συνάνθρωπό του το κάθε νεοφίλι;

η χειρότερη μορφή υπανθρώπου

[BaKXOS_Lysios]

Ποτέ δεν κατάλαβα πως και γιατί ο άνθρωπος μπορεί να ξεπέσει σε αυτό το νεκροζωντανο θλιβερό θέαμα και κάθε φορά όσες φορές το έχω δει μπροστά μου ανατριχιαζω.

[Perseus1966]

Ποτέ δεν κατάλαβα πως και γιατί ο άνθρωπος μπορεί να ξεπέσει σε αυτό το νεκροζωντανο θλιβερό θέαμα και κάθε φορά όσες φορές το έχω δει μπροστά μου ανατριχιαζω.

Τι να πω δοξα το θεω δεν εμπλεξα ποτε με ναρκωτικα ,πρεπει να ειναι τρομερος ο εθισμος

[Perseus1966]

Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply
Share
Tweet
Linkedin
Email
Print

For Immediate Release:
August 09, 2022

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine to allow healthcare providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection. This will increase the total number of doses available for use by up to five-fold. The EUA also allows for use of the vaccine in individuals younger than 18 years of age determined to be at high risk of monkeypox infection; in these individuals JYNNEOS is administered by subcutaneous injection.

“In recent weeks the monkeypox virus has continued to spread at a rate that has made it clear our current vaccine supply will not meet the current demand,” said FDA Commissioner Robert M. Califf, M.D. “The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all impacted individuals. By increasing the number of available doses, more individuals who want to be vaccinated against monkeypox will now have the opportunity to do so.”

JYNNEOS, the Modified Vaccinia Ankara (MVA) vaccine, was approved in 2019 for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. JYNNEOS is administered beneath the skin (subcutaneously) as two doses, four weeks (28 days) apart. For individuals 18 years of age and older determined to be at high risk of monkeypox infection, the EUA now allows for a fraction of the JYNNEOS dose to be administered between the layers of the skin (intradermally). Two doses of the vaccine given four weeks (28 days) apart will still be needed. There are no data available to indicate that one dose of JYNNEOS will provide long-lasting protection, which will be needed to control the current monkeypox outbreak.

About Monkeypox
Updated July 22, 2022
Print
Monkeypox is a rare disease caused by infection with the monkeypox virus. Monkeypox virus is part of the same family of viruses as variola virus, the virus that causes smallpox. Monkeypox symptoms are similar to smallpox symptoms, but milder, and monkeypox is rarely fatal. Monkeypox is not related to chickenpox.

Monkeypox was discovered in 1958 when two outbreaks of a pox-like disease occurred in colonies of monkeys kept for research. Despite being named “monkeypox,” the source of the disease remains unknown. However, African rodents and non-human primates (like monkeys) might harbor the virus and infect people.

The first human case of monkeypox was recorded in 1970. Prior to the 2022 outbreak, monkeypox had been reported in people in several central and western African countries. Previously, almost all monkeypox cases in people outside of Africa were linked to international travel to countries where the disease commonly occurs or through imported animals. These cases occurred on multiple continents.